Answers are grounded in this paper and cite their sources.
: Through decades of research, the literature has accumulated many publications investigating the therapeutic effects of MAO inhibitors (MAOIs) on various neurological conditions, such as Alzheimer's disease (AD), Parkinson's disease (PD), and depression. We envision that MAO literature will continue to grow steadily, with more new therapeutic candidates being tested for better management of neurological conditions, in particular, with the development of multi-target acting drugs against neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Yeung et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: